Browse the evidence

Adverse environmental conditions during early somatic development (fetal/infancy) increase the lifelong risk of chronic diseases such as obesity, diabetes, and cardiovascular disease through persistent metabolic and physiological programming.

Your health trajectory is influenced by your early environment, not just your current habits. While you cannot change your birth weight or early nutrition, understanding this link helps explain why certain metabolic risks exist and underscores the importance of maintaining a healthy lifestyle to counteract early programming.

Rapid postnatal weight gain ('catch-up growth') in low-birth-weight infants significantly increases the risk of developing cardiovascular disease and metabolic syndrome in adulthood.

If your baby was born small, aim for steady, healthy growth rather than rapid weight gain. Rapid 'catch-up' growth can increase the risk of heart disease and diabetes later in life. Consult your pediatrician for a growth plan that balances immediate health with long-term metabolic risk.

Maternal and neonatal nutritional status (both under- and over-nutrition) induces stable epigenetic modifications (DNA methylation, histone modification, miRNA) that program offspring susceptibility to metabolic syndrome, insulin resistance, and obesity in adulthood.

For expectant parents: Prioritize balanced nutrition (avoiding both severe restriction and excessive high-fat/sugar diets) during pregnancy and early infancy. This is not just about birth weight, but about programming the child's long-term metabolic health and reducing the risk of future obesity and diabetes through epigenetic mechanisms.

Metabolic disruptors can cause transgenerational inheritance of obesity and metabolic dysfunction, affecting offspring (F3 generation) who were never directly exposed to the chemical.

Be aware that your metabolic health may be influenced by your parents' and grandparents' environmental exposures. While you cannot change the past, you can protect your children by minimizing their exposure to plastics and environmental chemicals.

Dietary antioxidants (specifically tea catechins, apple polyphenols, blueberry anthocyanins, and soybean isoflavones) extend the mean lifespan of Drosophila melanogaster by upregulating endogenous antioxidant enzymes (SOD, CAT) and modulating longevity-related genes (Mth, Rpn11).

Incorporate antioxidant-rich foods like green tea, apples, blueberries, and soy into your diet. While this may support your body's natural defense against oxidative stress, it is not a guaranteed method for extending human lifespan, as current evidence is primarily from animal models.

Mild mitochondrial stress and modest increases in mitochondrial ROS levels increase lifespan in C. elegans, demonstrating that ROS acts as a beneficial signaling molecule rather than solely as a damaging agent.

Do not assume that neutralizing all free radicals is beneficial. The body uses mild mitochondrial stress (ROS) as a signal to activate protective mechanisms (hormesis). High-dose antioxidant supplements may interfere with these signals and potentially increase mortality risk, so focus on lifestyle factors that induce mild stress (like exercise) rather than suppressing ROS with supplements.

For heart failure treatment, diuretics are more effective than exercise interventions in reducing mortality.

If you have heart failure, taking prescribed diuretics is more effective than exercise for preventing death. However, exercise is still safe and recommended as part of your overall care plan, as it does not appear to cause harm and may improve functional capacity.

Pharmacological clearance of senescent cells using senolytics (specifically dasatinib and quercetin) extends health span and reduces age-related pathologies in mouse models.

This paper describes a preclinical strategy using specific drugs (senolytics) to clear aged cells. It is not a DIY protocol. The findings suggest that targeting cellular aging mechanisms is a viable path for extending health span, but human application requires further clinical trials to establish safety and efficacy.

Genetic ablation of senescent cells using the INK-ATTAC transgenic system delays age-related phenotypes and extends lifespan in mice.

This is a foundational scientific finding showing that removing senescent cells can extend life in mice. It provides the biological rationale for developing drugs (senolytics) to do the same in humans, but the genetic method itself is not a human intervention.

Constitutive responses to stress and DNA damage, including upregulation of heat shock proteins and proteases, are observed with age in Drosophila and worms, representing a conserved transcriptomic response to cellular damage.

In flies and worms, aging is associated with an upregulation of stress response genes like heat shock proteins. This suggests an attempt by the cell to cope with accumulated damage, although this pattern is less clear in mammals.

Administration of the bioactive peptide adropin34-76 improves glucose tolerance and insulin sensitivity in diet-induced obese mice by enhancing skeletal muscle insulin signaling and shifting fuel preference toward glucose oxidation.

This research suggests that the peptide hormone adropin can improve how the body processes glucose and insulin in obese individuals. It works by enhancing insulin signaling in muscles and shifting the body's fuel preference from fat to glucose. While this is a peptide therapy not yet available for general use, it highlights the importance of hormonal balance in metabolic health and offers a potential future therapeutic avenue for insulin resistance.

The efficacy of GIP-GLP-1 co-agonists may be explained by biased agonism and altered receptor internalization, which prevents the desensitization seen with pure GIP agonists.

The superior effect of co-agonists like tirzepatide may be due to their specific molecular design, which alters how receptors are signaled and internalized, preventing the 'shut down' (desensitization) that occurs with pure GIP agonists.

Intermittent fasting worsens glucose tolerance and induces beta-cell death in mice with lysosomal dysfunction (LAMP2 deficiency) or impaired autophagosome formation (BECN1 deficiency).

If you have underlying cellular recycling defects, fasting might damage your pancreas. Consult a doctor before trying IF if you have known metabolic disorders.

Shorter telomeres in tumor tissue (breast, colon, prostate) are associated with advanced disease state, faster progression, and poorer survival, whereas leukocyte telomere length (LTL) shows inconsistent associations with cancer risk.

If you have cancer, shorter telomeres in the tumor tissue often signal a more aggressive disease. However, a blood test for telomere length (LTL) is not yet a reliable way to predict if you will get cancer, as research findings are inconsistent. Focus on proven risk reduction strategies rather than LTL testing for cancer prediction.

High-salt diets can enhance antitumor immunity in melanoma and lung cancer by promoting the differentiation of M1-like macrophages and increasing the infiltration and function of CD8+ T cells.

For patients with melanoma or lung cancer, high-salt intake might boost immune response, but this is a complex trade-off. Do not increase salt intake without consulting your oncologist, as it may not be suitable for everyone, especially those with heart conditions.

Tomatidine extends lifespan and healthspan in C. elegans by inducing mitophagy through the SKN-1/Nrf2 pathway.

Tomatidine, found in unripe tomatoes, may support healthy aging by clearing damaged mitochondria. However, current evidence is limited to worms and cell cultures. No human dosage or safety data exists yet. Do not self-prescribe high doses based on this research.

Overexpression of the mitochondrial deacetylase SIRT3 protects hepatocytes from lipotoxicity by promoting both macroautophagy (lipophagy) and chaperone-mediated autophagy (CMA) through the activation of the AMPK-ULK1 pathway.

This research highlights that maintaining healthy mitochondrial function and NAD+ levels (via exercise, fasting, or metabolic health) may support SIRT3 activity, which in turn helps the liver clear excess fat through autophagy. It suggests that strategies improving metabolic flexibility are more effective than targeting single enzymes in isolation.

SIRT3 enhances mitochondrial energetics by directly deacetylating long-chain acyl-CoA dehydrogenase and promoting lipid droplet dispersion on detyrosinated microtubules.

Improving mitochondrial health through exercise and metabolic conditioning may support the enzymes that break down fats for energy. This suggests that a healthy liver relies on both clearing fat (autophagy) and efficiently burning it (mitochondrial function).

CTRP9 is a potent cardioprotective adipokine that attenuates acute ischemia/reperfusion injury and mitigates pathologic ventricular remodeling post-MI, primarily via PKA-dependent pathways.

CTRP9 is a protein produced by the heart and fat that helps protect the heart after a heart attack. While not yet a standard treatment, maintaining metabolic health may support natural CTRP9 levels, which help reduce scarring and improve heart function after injury.

Sarcolemmal ceramide accumulation decreases mitochondrial state 3 respiration and increases proton leak, thereby impairing mitochondrial function.

High levels of ceramide in muscle cells can damage mitochondrial function, leading to reduced energy production and increased proton leak. This contributes to insulin resistance. Maintaining mitochondrial health through exercise may help mitigate these effects.

The splicing factor SFA-1 (SF1 homolog) promotes longevity in C. elegans, and its depletion compromises the longevity benefits of caloric restriction.

Caloric restriction remains a key longevity strategy; its mechanism may involve splicing factors like SF1 homologs.

The splicing shift toward ING1a over ING1b promotes cellular senescence and prevents apoptosis, contributing to the maintenance of the senescent state.

No direct human intervention recommended.

GLP-1 receptor stimulation attenuates the reward effects of psychostimulants (cocaine and amphetamine) and nicotine, suggesting a role for endogenous GLP-1 in curbing drug reward.

GLP-1 based therapies may reduce the reward of addictive substances like cocaine, amphetamine, and nicotine. This suggests a potential future use in addiction treatment, particularly for reducing the 'high' or craving associated with these substances. However, this is currently based on animal studies.